BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21371446)

  • 1. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.
    Mori N; Ishikawa C; Senba M; Kimura M; Okano Y
    Biochem Pharmacol; 2011 May; 81(9):1106-15. PubMed ID: 21371446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
    Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
    Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
    Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
    J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
    Libertini S; Abagnale A; Passaro C; Botta G; Barbato S; Chieffi P; Portella G
    Endocr Relat Cancer; 2011 Feb; 18(1):129-41. PubMed ID: 21071467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.
    Wilkinson RW; Odedra R; Heaton SP; Wedge SR; Keen NJ; Crafter C; Foster JR; Brady MC; Bigley A; Brown E; Byth KF; Barrass NC; Mundt KE; Foote KM; Heron NM; Jung FH; Mortlock AA; Boyle FT; Green S
    Clin Cancer Res; 2007 Jun; 13(12):3682-8. PubMed ID: 17575233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
    Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
    Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.
    Tomita M; Tanaka Y; Mori N
    Int J Cancer; 2010 Oct; 127(7):1584-94. PubMed ID: 20091867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.
    Zekri A; Ghaffari SH; Yaghmaie M; Estiar MA; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
    Mol Neurobiol; 2016 Apr; 53(3):1808-1823. PubMed ID: 25752998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aurora kinase inhibitors as anti-cancer therapy.
    Lok W; Klein RQ; Saif MW
    Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
    Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
    Zhang L; Zhang S
    J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
    Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
    Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA.
    Zekri A; Mesbahi Y; Ghanizadeh-Vesali S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Anticancer Drugs; 2017 Sep; 28(8):841-851. PubMed ID: 28639950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
    Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
    Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
    Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
    Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
    Guo J; Anderson MG; Tapang P; Palma JP; Rodriguez LE; Niquette A; Li J; Bouska JJ; Wang G; Semizarov D; Albert DH; Donawho CK; Glaser KB; Shah OJ
    Pharmacogenomics J; 2009 Apr; 9(2):90-102. PubMed ID: 19188929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro.
    Tomita M; Mori N
    Cancer Sci; 2010 May; 101(5):1204-11. PubMed ID: 20180813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
    Tao Y; Zhang P; Girdler F; Frascogna V; Castedo M; Bourhis J; Kroemer G; Deutsch E
    Oncogene; 2008 May; 27(23):3244-55. PubMed ID: 18084327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative effect of Aurora kinase targeting in mesothelioma.
    Crispi S; Fagliarone C; Biroccio A; D'Angelo C; Galati R; Sacchi A; Vincenzi B; Baldi A; Verdina A
    Lung Cancer; 2010 Dec; 70(3):271-9. PubMed ID: 20371132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.